Alcohol Misuse in Patients with Psoriasis: Identification and Relationship to Disease Severity and Psychological Distress
Overview
Authors
Affiliations
Background: Moderate to severe psoriasis is associated with increased alcohol intake and excessive mortality from alcohol-related causes. Alcohol biomarkers provide an objective measure of alcohol consumption. Carbohydrate-deficient transferrin (CDT) is the single most sensitive and specific alcohol biomarker.
Objectives: To assess alcohol consumption in a cohort of patients with moderate to severe psoriasis using standard alcohol screening questionnaires and biomarkers. We investigated whether there was an association between alcohol intake, anxiety, depression and disease severity.
Methods: Consecutive patients with chronic plaque psoriasis were recruited and completed a range of anonymized assessments. Psoriasis severity, anxiety and depression, and the impact of psoriasis on quality of life were assessed. Alcohol screening questionnaires were administered. Blood specimens were taken and γ-glutamyltransferase (γGT) and CDT were measured.
Results: A total of 135 patients completed the study. Using validated questionnaires, between 22% and 32% had difficulties with alcohol. Seven per cent had CDT > 1·6% indicating a heavy alcohol intake. The Alcohol Use Disorders Identification Test (AUDIT) questionnaire was superior to other validated questionnaires in detecting alcohol misuse. There were no significant associations between measures of excessive alcohol consumption and disease severity. Excessive alcohol intake as measured by the CAGE questionnaire was associated with increased depression (P = 0·001) but other measures of alcohol excess did not correlate with psychological distress. Men had significantly more difficulties with alcohol than women (P < 0·001).
Conclusion: Alcohol misuse is common in patients with moderate to severe psoriasis. Screening with the AUDIT questionnaire and CDT may allow the identification of patients who are misusing alcohol and allow appropriate intervention.
Jordan A, Naslund-Koch C, Vedel-Krogh S, Bojesen S, Skov L JAAD Int. 2024; 15:197-205.
PMID: 38707928 PMC: 11066682. DOI: 10.1016/j.jdin.2024.03.003.
Bellinato F, Chiricozzi A, Piaserico S, Targher G, Gisondi P Int J Mol Sci. 2022; 23(21).
PMID: 36361639 PMC: 9658165. DOI: 10.3390/ijms232112849.
Alcohol and Psoriasis for the Dermatologist: Know, Screen, Intervene.
Kearney N, Kirby B Am J Clin Dermatol. 2022; 23(6):881-890.
PMID: 35997945 PMC: 9576661. DOI: 10.1007/s40257-022-00713-z.
Jalenques I, Bourlot F, Martinez E, Pereira B, DIncan M, Lauron S Acta Derm Venereol. 2022; 102:adv00769.
PMID: 35604236 PMC: 9558761. DOI: 10.2340/actadv.v102.1386.
Alcohol in Psoriasis-From Bench to Bedside.
Szentkereszty-Kovacs Z, Gaspar K, Szegedi A, Kemeny L, Kovacs D, Torocsik D Int J Mol Sci. 2021; 22(9).
PMID: 34067223 PMC: 8125812. DOI: 10.3390/ijms22094987.